86 related articles for article (PubMed ID: 32476108)
1. NUC-1031 in biliary tract cancer: from bench to bedside and back?
Boyd LNC; Peters GJ; Kazemier G; Giovannetti E
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1011-1014. PubMed ID: 32476108
[TBL] [Abstract][Full Text] [Related]
2. NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
Kapacee ZA; Knox JJ; Palmer D; Blagden SP; Lamarca A; Valle JW; McNamara MG
Med Oncol; 2020 Jun; 37(7):61. PubMed ID: 32529264
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.
Arora M; Bogenberger JM; Abdelrahman A; Leiting JL; Chen X; Egan JB; Kasimsetty A; Lenkiewicz E; Malasi S; Uson PLS; Nagalo BM; Zhou Y; Salomao MA; Kosiorek HE; Braggio E; Barrett MT; Truty MJ; Borad MJ
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1063-1078. PubMed ID: 32440762
[TBL] [Abstract][Full Text] [Related]
4. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
Sarr A; Bré J; Um IH; Chan TH; Mullen P; Harrison DJ; Reynolds PA
Sci Rep; 2019 May; 9(1):7643. PubMed ID: 31113993
[TBL] [Abstract][Full Text] [Related]
5. In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)".
Ricci AD; Rizzo A; Brandi G
Oncologist; 2021 May; 26(5):e902. PubMed ID: 33539601
[TBL] [Abstract][Full Text] [Related]
6. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for the biliary tract cancers: moving toward improved survival time.
Romiti A; D'Antonio C; Zullo A; Sarcina I; Di Rocco R; Barucca V; Durante V; Marchetti P
J Gastrointest Cancer; 2012 Sep; 43(3):396-404. PubMed ID: 22328060
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
Blagden SP; Rizzuto I; Suppiah P; O'Shea D; Patel M; Spiers L; Sukumaran A; Bharwani N; Rockall A; Gabra H; El-Bahrawy M; Wasan H; Leonard R; Habib N; Ghazaly E
Br J Cancer; 2018 Oct; 119(7):815-822. PubMed ID: 30206366
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy and histological stratification of biliary tract cancers.
Cariati A; Piromalli E
Oncology; 2012; 82(6):352-3. PubMed ID: 22677952
[No Abstract] [Full Text] [Related]
10. Biliary tract cancer stem cells - translational options and challenges.
Mayr C; Ocker M; Ritter M; Pichler M; Neureiter D; Kiesslich T
World J Gastroenterol; 2017 Apr; 23(14):2470-2482. PubMed ID: 28465631
[TBL] [Abstract][Full Text] [Related]
11. Toward personalized treatment of advanced biliary tract cancers.
Geynisman DM; Catenacci DV
Discov Med; 2012 Jul; 14(74):41-57. PubMed ID: 22846202
[TBL] [Abstract][Full Text] [Related]
12. Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells
Slusarczyk M; Serpi M; Ghazaly E; Kariuki BM; McGuigan C; Pepper C
J Med Chem; 2021 Jun; 64(12):8179-8193. PubMed ID: 34085825
[TBL] [Abstract][Full Text] [Related]
13. Emerging molecular target antagonists for the treatment of biliary tract cancer.
Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F
Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
[TBL] [Abstract][Full Text] [Related]
14. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
[TBL] [Abstract][Full Text] [Related]
15. Optimum chemotherapy for the management of advanced biliary tract cancer.
Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
[TBL] [Abstract][Full Text] [Related]
16. [Surgical outcome of biliary tract cancer with neoadjuvant chemotherapy].
Kato A; Shimizu H; Yoshidome H; Otsuka M; Furukawa K; Yoshitomi H; Takeuchi D; Takayashiki T; Kuboki S; Suzuki D; Nakajima M; Miyazaki M
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1486-9. PubMed ID: 23133873
[No Abstract] [Full Text] [Related]
17. [Surgical outcome of biliary tract cancer with postoperative chemotherapy].
Sugawara G; Ebata T; Yokoyama Y; Igami T; Kokuryo T; Tsunoda N; Fukaya M; Uehara K; Itatsu K; Yoshioka Y; Nagino M
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1483-5. PubMed ID: 23130375
[No Abstract] [Full Text] [Related]
18. Emerging treatment with systemic chemotherapy and targeted agents for biliary cancers.
Boku N
Curr Opin Investig Drugs; 2010 Jun; 11(6):653-60. PubMed ID: 20496260
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib plus trametinib in patients with BRAF
Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
[TBL] [Abstract][Full Text] [Related]
20. Second-line therapies in advanced biliary tract cancers.
Tella SH; Kommalapati A; Borad MJ; Mahipal A
Lancet Oncol; 2020 Jan; 21(1):e29-e41. PubMed ID: 31908303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]